Trade Bristol Myers ^BMY

BMY Maintains Rating by Morgan Stanley -- Price Target Raised to

5 Dividend Stocks With Fortress-Like Coverage and Room for Things to Go Wrong

Bristol Myers Squibb (BMY) Expands CAMZYOS Approval, Is The Stock Still A Bargain?

Takeda's zasocitinib raises bar for oral psoriasis drugs

Bristol Myers Squibb (NYSE:BMY) Stock Rating Cut to Market Perform at Leerink Partners - Markets Daily

Bristol Myers (BMY) Stock is Trading Below 10 Times Forward Earnings. Here's Why it Matters - Insider Monkey

Top Pharmaceutical Stocks To Follow Now - October 5th - Markets Daily

Top Pharmaceutical Stocks To Follow Now - October 5th - Stock Observer

Pfizer's Turnaround Could Be Bigger Than Investors Think, Set For 20% Upside

Bristol Myers Squibb Deepens Commitment to Healthcare

AbbVie (ABBV) vs Bristol Myers (BMY): Which is a Better Stock to Buy?

CX Institutional Sells 208,135 Shares of Bristol Myers Squibb Company $BMY

Eli Lilly & Co (LLY) Gets a Buy from RBC Capital

BMY Stock Gets Stronger EPS Forecast from Zacks Research - Daily Political

Urine cell-free RNA for bladder cancer detection and treatment response prediction

Analysts unshaken by patient death in BMS lung fibrosis trial

BMY: Legacy Drug Erosion Looms, Oncology Platforms And AI Hold The Upside

RBC Capital Keeps Their Hold Rating on Merck & Company (MRK)

What is Johnson & Johnson's (JNJ) Economic Moat, and is it Widening or Narrowing?

Heparin-Induced Thrombocytopenia Market: Steady Growth Driven by Emerging Non-Heparin Anticoagulants and Novel Therapies by 2034 | ABNewswire

"There is growing emphasis on B-cell maturation antigen-targeted cell therapies to treat Multiple Myeloma"

Five-year survival with neoadjuvant therapy in melanoma: updated pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)

Bristol Myers Squibb Says FDA Approves Heart Disease Treatment Camzyos for Pediatric Patients | Morningstar

Promising Pharmaceutical Stocks Worth Watching - September 30th

Bristol Myers Squibb's Dividend Sustainability Hinges on One Critical Cash Flow Metric - 24/7 Wall St.

BMY: Growth Portfolio Carries The Case, Patent Cliffs Still Set The Limits

How Strong Phase 3 MRD Data for ZENBEXUS in Myeloma Could Impact Bristol Myers Squibb (BMY) Investors

Heart Failure Clinical Trial Drug Development Pipeline Expands with Contributions from 70+ Key Companies | DelveInsight | ABNewswire

Sugar-rich foods exacerbate antibiotic-induced microbiome disruption

Adrenocortical Carcinoma Market Poised for Sustained Growth Amid Advancements in Treatment and Clinical Innovation by 2036- DelveInsight | Orphagen Pharma, Corcept Therapeutics, Cytovation, Merck | ABNewswire

Bristol Myers Squibb (BMY) Reported 41.1% MRD Negative Responses In Phase 3 Trial

Could Bristol-Myers Squibb (BMY)'s New Myeloma Data Reshape its Growth Outlook?

A prospective observational study of treatment sequencing with regorafenib and FTD/TPI in metastatic colorectal cancer: The OSERO study

A synthetic lethal drug for microsatellite instability cancers

Acute Myocardial Infarction Market: Expanding Therapeutic Innovation, Secondary Prevention Strategies, and Emerging Pipeline Therapies to Drive Growth Through 2036 | ABNewswire

Myasthenia Gravis Clinical Trial Pipeline Gains Momentum: 28+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight | ABNewswire

Bristol-Myers Squibb (BMY) is Building its Next Growth Engine. Can It Replace Lost Revenue?

Promising Pharmaceutical Stocks To Research - September 28th - Zolmax

Lupin Receives Tentative Approval From U.S. FDA For Novel Apixaban Oral Suspension

Lupin Secures FDA Tentative Approval for Eliquis Generic, Targeting $3.3 Billion Market, ETPharma

Care Within Reach: How the Bristol Myers Squibb Foundation Is Strengthening Health Systems Across Africa

Lupin receives tentative approval for anticoagulant Apixaban from US FDA

Bristol Myers Squibb (NYSE:BMY) versus Cocrystal Pharma (NASDAQ:COCP) Financial Review - Markets Daily

Comparing Bristol Myers Squibb (NYSE:BMY) and Cocrystal Pharma (NASDAQ:COCP) - Stock Observer

Comparing Bristol Myers Squibb (NYSE:BMY) and Bausch Health Cos (NYSE:BHC) - Stock Observer

Global burden of venous thromboembolism: incidence and outcome estimates of deep-vein thrombosis and pulmonary embolism

317,360 Bristol Myers Squibb Company $BMY Shares Bought by Envestnet Asset Management Inc.

Novartis (NVS) and Bristol Myers (BMY) Pause Autoimmune CAR-T Studies. Can Their Programs Recover?

Daratumumab ± pomalidomide maintenance after salvage autologous transplantation in relapsed multiple myeloma: a phase 2 study

Bristol Myers Squibb patents new NIK inhibitors

Zacks Research Upgrades Bristol Myers Squibb (NYSE:BMY) to "Strong-Buy" - Stock Observer

24,285 Bristol Myers Squibb Company $BMY Shares Acquired by Envestnet Portfolio Solutions Inc.

AI in Clinical Trials Market Set for Transformative Growth Through 2040, Unlocking Opportunities Across Trial Phases, Therapeutic Areas, End Users and Key Global Regions | Valuespectrum.com

Bristol Myers Squibb (BMY) Adds Restricted Pharmacy Path For New Myeloma Drug

Financial Contrast: Orion OYJ (OTCMKTS:ORINY) & Bristol Myers Squibb (NYSE:BMY) - Markets Daily

Leveraging Brazil's Health Networks for Early Lung Cancer Detection | Morningstar

Engineers Gate Manager LP Decreases Stake in Bristol Myers Squibb Company $BMY

Best Income Stocks to Buy for September 24th

Bristol Myers Squibb (NYSE:BMY) and Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Financial Survey - Zolmax

Crohns' Disease Clinical Trial Drug Development Pipeline Expands with Contributions from 90+ Key Companies | DelveInsight | ABNewswire

Bristol Myers Squibb (NYSE:BMY) versus Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Head to Head Contrast - Daily Political

State Street Corp Has $6.09 Billion Holdings in Bristol Myers Squibb Company $BMY

State Street Corp Has $6.09 Billion Stock Position in Bristol Myers Squibb Company $BMY - Stock Observer

Glioblastoma Market Set to Expand from USD 799 Million as New Therapies and a Robust Pipeline Advance Through 2034Glioblastoma (GBM) Market | ABNewswire

Performance and safety of a multi-cancer early detection test: the PATHFINDER 2 study

Trastuzumab plus nivolumab with gemcitabine and cisplatin as first-line therapy for HER2-positive unresectable biliary tract cancer: a phase 1b/2 trial

BMY vs GILD: Which Biotech Stock Looks More Attractive Now?

Pancreatic Endocrine Tumor Market Outlook 2034: Growth Trends, Competitive Landscape, and Future Opportunities - DelveInsight | ABNewswire

Did VOXZOGO's Hypochondroplasia Win and New R&D Hire Just Reframe BioMarin's (BMRN) Investment Narrative?

BMY vs. ARGX: Which Stock Is the Better Value Option?

Pfizer's Dividend Yield Is Enormous. But Is the Payout Still Growing?

Bristol Myers Squibb (BMY) Funds India Lung Cancer Screening Research Beyond Smoking

Bristol-Myers Squibb (BMY), What Is Behind The Fresh Attention?

The exposome and inflammatory bowel disease: a framework for primary and primordial prevention

Bristol Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know

Bristol Myers Squibb Presents Sotyktu (deucravacitinib) Data Showing Durable Efficacy, Consistent Safety in Adults with Psoriatic Arthritis Over Two Years | Morningstar

BMY: Late Stage Pipeline Milestones Will Drive Future Re Rating Narrative

Bristol Myers Squibb Company Declares Quarterly Dividend of $0.63 (NYSE:BMY)

Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know

Bristol Myers Squibb Declares Quarterly Dividend As Part Of Ongoing Shareholder Return Strategy

Bristol Myers Squibb identifies new muscarinic receptor agonists | BioWorld

Dr Reddy's forays into Indian biosimilar immuno-oncology market

Dr Reddy's Launches Nivorz: A Game-Changer in India's Cancer Treatment Market, ETPharma

Dr Reddy's launches Opdivo biosimilar Nivorz in India, enters immuno-oncology segment

Zacks Research Has Positive Outlook for BMY Q3 Earnings - Zolmax

The Bull Case For Bristol Myers Squibb (BMY) Could Change Following Arlo-cel's Positive Phase 2 Myeloma Data

Lockheed's Pension Risk Transfer Appeal Tests Retiree Rights

Zacks Research Issues Positive Estimate for BMY Earnings - Daily Political

RBC Capital Sticks to Their Buy Rating for AstraZeneca (AZN)

RBC Capital Sticks to Their Buy Rating for Roche Holding AG (RHHVF)

RBC Capital Sticks to Their Buy Rating for AbbVie (ABBV)

GlaxoSmithKline (GSK) Gets a Hold from RBC Capital

RBC Capital Sticks to Their Hold Rating for Merck & Company (MRK)

RBC Capital Sticks to Their Hold Rating for Bristol-Myers Squibb (BMY)

RBC Capital Keeps Their Hold Rating on Novartis AG (NOVN)

RBC Capital Sticks to Their Buy Rating for Eli Lilly & Co (LLY)

Should You Buy Bristol Myers Squibb Stock Right Now for the Yield Alone?

Clinical usability of an explainable AI decision support tool and evaluation of multimodal models in NSCLC